Target Price | $169.61 |
Price | $162.85 |
Potential | 4.15% |
Number of Estimates | 18 |
18 Analysts have issued a price target Johnson & Johnson 2026 . The average Johnson & Johnson target price is $169.61. This is 4.15% higher than the current stock price. The highest price target is $190.00 16.67% , the lowest is $150.00 7.89% . | |
A rating was issued by 23 analysts: 11 Analysts recommend Johnson & Johnson to buy, 12 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Johnson & Johnson stock has an average upside potential 2026 of 4.15% . Most analysts recommend the Johnson & Johnson stock at Hold. |
15 Analysts have issued a sales forecast Johnson & Johnson 2025 . The average Johnson & Johnson sales estimate is $90.0b . This is 1.31% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $91.6b 3.11% , the lowest is $89.4b 0.62% .
This results in the following potential growth metrics:
2024 | $88.8b | 4.31% |
---|---|---|
2025 | $90.0b | 1.31% |
2026 | $93.6b | 4.01% |
2027 | $97.1b | 3.76% |
2028 | $102b | 5.08% |
2029 | $106b | 4.32% |
10 Analysts have issued an Johnson & Johnson EBITDA forecast 2025. The average Johnson & Johnson EBITDA estimate is $33.7b . This is 19.32% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $38.1b 35.02% , the lowest is $30.4b 7.71% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $28.2b | 5.01% |
---|---|---|
2025 | $33.7b | 19.62% |
2026 | $34.7b | 3.03% |
2027 | $37.6b | 8.36% |
2028 | $35.9b | 4.52% |
2029 | $38.3b | 6.58% |
2024 | 31.71% | 8.93% |
---|---|---|
2025 | 37.44% | 18.08% |
2026 | 37.09% | 0.93% |
2027 | 38.73% | 4.42% |
2028 | 35.20% | 9.11% |
2029 | 35.96% | 2.16% |
5 Johnson & Johnson Analysts have issued a net profit forecast 2025. The average Johnson & Johnson net profit estimate is $22.4b . This is 60.50% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $25.6b 83.54% , the lowest is $18.5b 32.24% .
This results in the following potential growth metrics and future Net Margins:
2024 | $13.9b | 4.70% |
---|---|---|
2025 | $22.4b | 60.78% |
2026 | $24.0b | 6.96% |
2027 | $20.0b | 16.34% |
2028 | $20.8b | 3.84% |
2029 | $21.8b | 4.86% |
2024 | 15.69% | 0.38% |
---|---|---|
2025 | 24.90% | 58.70% |
2026 | 25.61% | 2.85% |
2027 | 20.65% | 19.37% |
2028 | 20.41% | 1.16% |
2029 | 20.51% | 0.49% |
5 Analysts have issued a Johnson & Johnson forecast for earnings per share. The average Johnson & Johnson <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $9.31 . This is 60.52% higher than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $10.65 83.62% , the lowest is $7.67 32.24% .
This results in the following potential growth metrics and future valuations:
2024 | $5.79 | 4.70% |
---|---|---|
2025 | $9.31 | 60.79% |
2026 | $9.96 | 6.98% |
2027 | $8.33 | 16.37% |
2028 | $8.65 | 3.84% |
2029 | $9.07 | 4.86% |
Current | 28.09 | 1.78% |
---|---|---|
2025 | 17.49 | 37.74% |
2026 | 16.35 | 6.52% |
2027 | 19.55 | 19.57% |
2028 | 18.83 | 3.68% |
2029 | 17.95 | 4.67% |
Based on analysts' sales estimates for 2025, the Johnson & Johnson stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 4.51 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 4.36 .
This results in the following potential growth metrics and future valuations:
Current | 4.56 | 8.31% |
---|---|---|
2025 | 4.51 | 1.20% |
2026 | 4.33 | 3.86% |
2027 | 4.17 | 3.62% |
2028 | 3.97 | 4.83% |
2029 | 3.81 | 4.15% |
Current | 4.41 | 6.86% |
---|---|---|
2025 | 4.36 | 1.29% |
2026 | 4.19 | 3.86% |
2027 | 4.04 | 3.62% |
2028 | 3.84 | 4.83% |
2029 | 3.68 | 4.15% |
Johnson & Johnson...
Analyst | Rating | Action | Date |
---|---|---|---|
Guggenheim |
Neutral
➜
Neutral
|
Unchanged | Mar 12 2025 |
Guggenheim |
Neutral
➜
Neutral
|
Unchanged | Mar 10 2025 |
B of A Securities |
Neutral
➜
Neutral
|
Unchanged | Mar 05 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Feb 19 2025 |
Guggenheim |
Neutral
➜
Neutral
|
Unchanged | Feb 03 2025 |
Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jan 28 2025 |
B of A Securities |
Neutral
➜
Neutral
|
Unchanged | Jan 23 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Guggenheim:
Neutral
➜
Neutral
|
Mar 12 2025 |
Unchanged
Guggenheim:
Neutral
➜
Neutral
|
Mar 10 2025 |
Unchanged
B of A Securities:
Neutral
➜
Neutral
|
Mar 05 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Feb 19 2025 |
Unchanged
Guggenheim:
Neutral
➜
Neutral
|
Feb 03 2025 |
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
Jan 28 2025 |
Unchanged
B of A Securities:
Neutral
➜
Neutral
|
Jan 23 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.